{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:04:57Z","timestamp":1763697897595,"version":"3.45.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115626","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T02:33:05Z","timestamp":1759545185000},"page":"115626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Questions on the mechanistic scope and clinical applicability of Kanglexin in hepatic fibrosis"],"prefix":"10.1016","volume":"166","author":[{"given":"Parth","family":"Aphale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Dokania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115626_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115545","article-title":"Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-\u03b2\/SMADS signaling pathway and glutathione metabolism","volume":"166","author":"Kou","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115626_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcmgh.2023.05.010","article-title":"In vivo and in vitro models to study liver fibrosis: mechanisms and limitations","volume":"16","author":"Lee","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.115626_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101828","article-title":"Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-\u03b2 production","volume":"78","author":"Song","year":"2023","journal-title":"Mol. Metab."},{"issue":"5","key":"10.1016\/j.intimp.2025.115626_bb0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/HEP.0000000000000319","article-title":"Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-\u03b2\/SMAD signaling","volume":"78","author":"Song","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2025.115626_bb0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2022.12.025","article-title":"Miglustat mitigates liver fibrosis through TGF-\u03b2\/Smad pathway suppression in hepatic stellate cells","volume":"642","author":"Iwanaga","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:57:54Z","timestamp":1763697474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925016170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"alternative-id":["S1567576925016170"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115626","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Questions on the mechanistic scope and clinical applicability of Kanglexin in hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115626"}}